Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1CNS 1

Conditions

Primary Graft Dysfunction 1Neurofibromatosis 1 1Liver Neoplasms 1Liver Failure, Acute 1Liver Failure 1Liver Diseases 1Carcinoma, Hepatocellular 1Attention Deficit Disorder with Hyperactivity 1

Interventions

Cyclophosphamide 741Cisplatin 688Gemcitabine 641Bevacizumab 616Carboplatin 605Paclitaxel 601Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 361Capecitabine 342Filgrastim 333Etoposide 330Dexamethasone 312Irinotecan 309pembrolizumab 282Leucovorin 274Cetuximab 268Cytarabine 242Erlotinib Hydrochloride 231Nivolumab 228Prednisone 227Trastuzumab 225Vincristine 221Bortezomib 221Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Completed × N-monoacetylcystine × Clear all
NCT04481048 2026-06-05

DoDNAC

Children's Hospital Medical Center, Cincinnati

Phase 2 Completed
25 enrolled 12 charts
CNS

Attention Deficit Disorder with Hyperactivity, Neurofibromatosis 1

NCT01394497 2013-02-18

Use of N-Acetylcysteine During Liver Procurement

Azienda Ospedaliera di Padova

Phase 2 Completed
140 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Liver Failure, Liver Failure, Acute, Primary Graft Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡